KMO has been shown to have increased activity in breast cancer compared to normal cells, specifically being upregulated on the protein level in the HER2+ subtype and having elevated transcription levels in the Triple Negative subtype [52, 53]. This evidence concerns the gene ERBB2 and breast carcinoma.